Advanced Renal Cell Carcinoma: Continuing to Refine the Role of Targeted Therapies

Each year, over 50,000 Americans learn that they have kidney cancer. Often a silent cancer, renal cell carcinoma (RCC) is the most common type of kidney cancer. Approximately 20% to 30% of patients present with metastatic RCC (mRCC), and 20% to 40% will develop mRCC after nephrectomy. Prognosis for patients with mRCC is poor, but expanding knowledge of the pathophysiology of the disease has contributed to the development of targeted therapies that have been shown to prolong survival, providing hope for many patients with RCC. With the plethora of new data on targeted therapies for RCC, clinicians are confronted with the challenge of applying emerging knowledge to clinical practice while adhering to treatment guidelines. Clinicians also face the challenges of managing treatment-related adverse events and determining if and when dose adjustments may be warranted. A review of clinical trial data, prognostic markers, common adverse events, treatment guidelines, and dosing strategies will be beneficial to clinicians who treat patients with RCC and ultimately improve patient care.

Available until March 31, 2011, this activity offers:
Physicians: 1.0 AMA PRA Category 1 Credit^™
Nurses: 1.0 contact hour

This activity is co-provided by The University of Michigan Medical School, SCEPTER™, EduPro Resources LLC, and Quintiles Medical Education.